Metoclopramide Pretreatment for Prevention of Pain on Propofol Injection:
A Randomized Placebo-Controlled Study

Muhammad Sazzad Hossain¹, Syed Ariful Islam², Md. Afzalur Rahman³, Md. Mahiuddin Alamgir⁴, Md. Waliullah⁵

Abstract

Background: Propofol, the most frequently used intravenous anaesthetic, is used for induction, maintenance of anaesthesia and for sedation in patients scheduled for routine elective surgical procedure. Pain on propofol injection still remains a considerable concern for the anaesthesiologist. Objective: Aim of this study was to observe the efficacy of metoclopramide as pretreatment for the prevention of pain caused by the propofol injection in patients undergoing elective surgery under general anaesthesia. Materials and method: A total of 80 patients were taken up in the study in the age group of 20 to 50 years of either sex, ASA grade I/II, scheduled for routine elective surgical procedure under general anesthesia with endotracheal intubation and using propofol as induction agent. The patients enrolled were divided randomly into two groups of 40 patients each. Group A received 10 mg metoclopramide IV diluted in 5 ml saline. Group B received 5 ml of normal saline as placebo before propofol injection. The patients were asked to report their pain according to the scale provided to them in the form of none, mild, moderate and severe after injection of propofol. Results: The overall incidence and severity of pain were significantly less in Group A (metoclopramide group) than in group B (placebo group) (p< 0.05). The incidence of mild and moderate pain in Group A versus group B was 15% vs 45% and 5% vs 25% respectively (p<0.05). The incidence of score ‘0’ (no pain) was higher in Group A (80%) than Group B (25%) (p< 0.05). Conclusion: Intravenous metoclopramide is effective for relief of pain on propofol injection without any significant side effects.

Key words: Metoclopramide; pain on propofol injection (POPI).

Introduction

Propofol is one of the most widely used drugs for induction of anaesthesia, whose common application is due to high clearance and fast awakening of patient.¹ Propofol induced anaesthesia is associated with adverse complications, including severe pain on injection, myoclonus, apnea, reduced blood pressure and rarely thrombophlebitis. The pain on propofol...
Injection (POPI) is one of the major side effects and its incidence varies from 28% to 90% in adults. The incidence of pain has been reported to be 80% to 90% in the case of injection in the back-of-hand vessels. Many patients reported severe pain after drug injection and some of them stated unbearable pain. The patients suffering from injection induced pain may experience anxiety, fear and ischaemia or even myocardial infarction. Instead, reducing the injection-induced pain increases patient's satisfaction and safety. The pain on propofol injection (POPI) is attenuated through various techniques, including injection of drugs at different rates and fluid injection at intervals, change in the temperature of the injectable fluid, or combination with other drugs. One of the most accepted ways is pretreatment with lidocaine. However, studies have shown that this method does not relieve pain completely, and the patient's problem will continue. Other studies have suggested methods for controlling POPI, including the injection of low doses of narcotics such as sufentanil and butorphanol, injection in large vessels, lignocaine injection together with tourniquet closure, and cold-warm propofol. Some researchers used magnesium, beta blocker, 5-HT3 receptor antagonists, Alpha2 agonists like dexmedetomidine and metoclopramide injection as a premedication for prevention of POPI.

Metoclopramide is a benzamide with both central and peripheral anti-emetic actions. In addition to this pharmacologic property, metoclopramide has local anaesthetic properties like those of lidocaine.

The present prospective comparative study tried to evaluate the outcome of pretreatment by metoclopramide 10 mg intravenously on pain on propofol injection (POPI) in comparison to placebo.

**Materials and method**

This was a randomized controlled double blind study conducted at National Institute of ENT (NIENT) Dhaka, Bangladesh, during March to May 2018. Eighty voluntarily consenting patients with American Society of Anesthesiologists (ASA) physical status class I and class II of either sex, aged 20-50 years who were scheduled to undergo elective surgical procedures that required general anesthesia with tracheal intubation were recruited into the study. The exclusion criteria included patients with known cardiac disorders, other systemic disorders of lungs, kidney and liver, pregnant patients, patients for emergency procedures, those allergic to propofol and metoclopramide and patients with difficult airway.

Patients were randomly divided into two groups. The study drug was administered by an anaesthesiologist who was blinded to the constituents of the drug. Group A (metoclopramide group) received 10 mg metoclopramide diluted in 5 ml normal saline and Group B (placebo group) received 5 ml normal saline.

Prior to surgery, the patients underwent thorough pre-anaesthetic check-up and required investigations. Patients were kept fasting for 8 hours. In the operation theatre, intravenous access was established with 20-gauge cannula in suitable vein on non-dominant hand and was infused with Ringer's lactate solution. Vital signs were measured by placing an electrocardiogram, a non-invasive blood pressure monitor, end tidal carbon-dioxide and a pulse oximeter on the patients. They were given 5 ml of pre-treatment solution, containing either metoclopramide (group A) or 5 ml normal saline (group B) intravenously after venous occlusion using blood pressure cuff around middle of the arm limiting inflation pressure to just above 50 mmHg and locked in order to be sure that venous outflow was completely restricted. One minute later, the occlusion of venous drainage was released. This was followed by injection of 1% propofol, one-fourth of the calculated dose was injected over 15 seconds later the patient was assessed for pain during injection of propofol on a scale between 0-3 developed by McCrirrick and Hunter. The responses were evaluated as 0 = no pain; 1 = mild pain (pain reported in response to questioning only, no behavioral signs);
2 = moderate pain (pain reported in response to questioning and accompanied by behavioral signs); and 3 = severe pain (strong vocal response or response accompanied by facial grimacing, arm withdrawal or tears).

After pain assessment the remaining propofol was injected. After induction, patients were intubated and anaesthesia was maintained with nitrous oxide, oxygen halothane and vecuronium. At the end of surgery, residual neuromuscular blockade was antagonised with 0.05 mg/kg of neostigmine and 0.02 mg/kg of atropine. Extubation was done when the patients were fully awake and obeying commands.

For comparison of quantitative variables between the two groups, the unpaired t-test and for qualitative variables the Chi-square test was used. The statistical level of significance was p<0.05.

Results
There is no significant demographic difference between the groups (Table I). Basal mean arterial pressure (MAP) and heart rate are comparable in both groups. There is no significant difference of MAP and heart rate between metoclopramide and control groups during pre-intubation or three minutes post-intubation period (p>0.05). (Table II)

The incidence of pain experienced in metoclopramide group (group A) is 20% and in group B (control group) is 75%, which is statistically significant p<0.05 (Table III). The severity of POPI is also lower in metoclopramide group than the control group (p<0.05) (Table III). The incidence of mild and moderate pain in Group A versus group B was 15% vs 45% and 5% vs 25% respectively, which were also statistically significant (p<0.05).

Discussion
The present study compared the efficacy of metoclopramide to placebo as pretreatment agent in decreasing the incidence and severity of pain on propofol injection (POPI) in patients undergoing elective surgery under general anaesthesia. This study result shows the incidence of pain experienced in metoclopramide group is 20% and in control group is 75% (p<0.05). The severity of POPI is also lower in metoclopramide group than in the control group (p<0.05). The incidence of mild and moderate pain in Group A versus group B was 15% vs 45% and 5% vs 25% respectively (p<0.05).

The pain alleviating effect of metoclopramide could be attributed to the facts that serotonin, (5-hydroxytryptamine [5-HT]), is a biological amine found in the brain and spinal cord and has a role in neurotransmission.18 Animal studies indicated that 5-HT3 antagonists reduce nociceptive responses of dorsal horn neurons when administered intrathecally by altering the 5-HT3 nociceptive receptors and this effect can be attributed to the antagonism to the stimulatory action of serotonin at 5-HT3 receptors that are
involved in the nociceptive pathways. Also, Ye et al found 5-HT3 antagonists to be 15 times more effective than lignocaine as a local anaesthetic when injected under the skin in equal amounts. Moreover, 5-HT3 antagonists had been found to have sodium channel blocking action like lignocaine.

Tamer et al showed in their study that metoclopramide 10 mg priming dose was as effective as lignocaine for prevention of propofol injection pain with an effect superior to 2.5 and 5 mg metoclopramide. These findings go in hand with Fujii & Nakayama who found the combination of lignocaine with metoclopramide is more effective than lignocaine alone for reducing pain on injection of propofol in a peripheral vein. Fujii & Shiga found metoclopramide is effective for reducing propofol injection pain, irrespective of patients' age but older people require and respond well to smaller doses. Fujii & Nakayama examined the effects of lignocaine administered with 3 different doses of metoclopramide or saline on pain of propofol injection in adults undergoing elective surgery and found that administration of lignocaine with metoclopramide in dose of 5 or 10 mg was associated with lower incidence of pain.

Fujii & Itakura compared the efficacy of lignocaine, metoclopramide, and flurbiprofenaxetil for reducing pain of propofol injection in adult surgical patients and reported an overall incidence of propofol-induced pain of 24%, 28% and 36%, respectively, compared with placebo with non-significant difference of incidence and severity between the treated groups. Present study is nearly comparable to study done by Fiji & Itakura where incidence of POPI by pretreatment with metoclopramide is 20% versus 28%.

It can be concluded that, venous priming with a dose of 10 mg metoclopramide administered with mid-arm tourniquet applied for one minute before propofol administration can reduce the incidence and severity of pain on propofol injection without significant adverse effects.

References


